Gimv Life Sciences Invest 2024

Private limited companyfounded 20251 yr activeKarel Oomsstraat 37, 2018 Antwerpen, BelgiumKBO/BCE: BE 1019.848.694

Gimv Life Sciences Invest 2024 is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €15.55M and a net result of €-862k. Its solvency ranks better than 95% of 5511 sector peers (fiscal year 2025). The company has been active since 2025 and the Belgian State Gazette contains no insolvency or warning signals.

Watch Print / PDF

Checked score

Outside the general model

Model not applicable to financial institutions

The health score weighs liquidity, leverage and margins against norms for trading and manufacturing companies. A bank, insurer or financial holding has a fundamentally different balance-sheet structure, so those ratios, and hence the score, carry no meaning here. That is why we show no financial axes either.

Credit advice for your own amount and term

Signals

Three signals. The signal on the left, the evidence on the right.

+raises risk○neutral

Young company

Founded in 2025, under 3 years, statistically higher risk.

KBO · incorporation date

Age against the risk zone

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-06-2026, 31 days ahead of the deadline.

NBB · 2 filings

Deviation from the deadline

2025

31 d early

2025

36 d early

← before the deadline after the deadline →

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

Financials · fiscal year 2025, abbreviated schema

Equity

€15.55M▲ 4,047%

2025 · €375k

2025: €375k

2025 → 2025

Net result

€-862k▼ 3,346%

2025 · €-25k

2025: €-25k

2025 → 2025

Total assets

€15.62M▲ 3,994%

2025 · €381k

2025: €381k

2025 → 2025

Solvency

99.6%▲ 1.3pp

2025 · 98.3%

2025: 98.3%

2025 → 2025

Multi-year overview

Every figure with its change against the year before

▲ rise ▼ fall

Line20252025Trend

Equity€375k-€15.55M▲ 4,047%

Operating result€-25k-€-214k▼ 756%

Net result€-25k-€-862k▼ 3,346%

Turnover and EBIT margin not published: the abbreviated schema does not require them.

Result per fiscal year

Operating resultNet result

Multiple fiscal year ends fall in the same calendar year; an annual trend is not displayed.

Balance-sheet composition

2025 in colour, 2025 as the grey bar beneath

Assets €15.62M

99.5%

Fixed assets €15.53M▲ 5,074%

Current assets €85k▲ 4.8%

Equity and liabilities €15.62M

99.6%

Equity €15.55M▲ 4,047%

Debt €66k▲ 911%

The debt ratio falls from 1.7% to 0.4%. Equity and debt are higher.

Key figures and ratios

2025 value · change against 2025

Solvency

99.6%▲

2025 · 98.3%

ROE

-5.5%▲

2025 · -6.7%

ROA

-5.5%▲

2025 · -6.6%

Debt

€66k▲

2025 · €7k

Debt ≤ 1 year

€66k▲

2025 · €7k

Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.

Filed annual accounts

As filed with the NBB · 2025 against 2025

Balance sheet Code20252025

Assets

Total assets20/58€381k€15.62M▲

Fixed assets21/28€300k€15.53M▲

Financial fixed assets28€300k€15.53M▲

Current assets29/58€81k€85k▲

Cash at bank and in hand54/58€81k€85k▲

Equity and liabilities

Total equity and liabilities10/49€381k€15.62M▲

Equity10/15€375k€15.55M▲

Contributions10/11€400k€16.44M▲

Profit (loss) carried forward14€-25k€-887k▼

Amounts payable17/49€7k€66k▲

Amounts payable within one year42/48€7k€66k▲

Trade debts44€7k€57k▲

Suppliers440/4€7k€57k▲

Taxes, remuneration and social security45-€8k

Taxes450/3-€8k

Income statement Code20252025

Other operating charges640/8€3k€55k▲

Gross operating margin9900€-22k€-159k▼

Operating profit (loss)9901€-25k€-214k▼

Financial income75/76B€201€4k▲

Recurring financial income75€201€4k▲

Financial charges65/66B€250€652k▲

Recurring financial charges65€250€2k▲

Non-recurring financial charges66B-€651k

Profit (loss) for the period before taxes9903€-25k€-862k▼

Profit (loss) for the period9904€-25k€-862k▼

Profit (loss) for the period to be appropriated9905€-25k€-862k▼

Appropriation of the result

Profit (loss) to be appropriated9906€-25k€-887k▼

Profit (loss) brought forward from the previous period14P-€-25k

The notes to these accounts (7 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

All 3Financial 1Filings 2

2026

30-06

NBB filing Annual accounts filed

fiscal year 2025 · abbreviated schema

2025

31-12

Financial Equity above €10MEq €15.55M ▲4047%

Equity rises from €375k to €15.55M.

25-09

NBB filing Annual accounts filed

fiscal year 2025 · abbreviated schema

Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors

no sitting director, no change since 2025

We have established no sitting directors for this company. We derive directors from published Gazette acts; while there are none, or none read, nothing appears here. That does not mean the company has none: the CBE keeps its own list of function holders, which we do not read.

21-05-2025 Resigned as Director

Location & real-estate footprint

Registered office, Antwerpen · 1 establishment unit since 2025

establishment The establishment unit on the map

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Karel Oomsstraat 372018 Antwerpen

Ground area

2,696 m²

Building footprint

1,209 m²

Volume, LiDAR